Current Advances in the Fecal Microbiota Transplantation and Its Application in the Hematologic Diseases--Review.
10.7534/j.issn.1009-2137.2019.01.051
- Author:
Ling QI
1
;
Fei LI
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanchang University.Nanchang 330006, Jiangxi Province, China.Institute of Hematology, Academy of Clinical Medicine Sciences of Jiangxi Province, Nanchang 330006, Jiangxi Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanchang University.Nanchang 330006, Jiangxi Province, China.Institute of Hematology, Academy of Clinical Medicine Sciences of Jiangxi Province, Nanchang 330006, Jiangxi Province, China.E-mail: yx021021@.sina.com.
- Publication Type:Journal Article
- MeSH:
Clostridium Infections;
Clostridium difficile;
Dysbiosis;
Fecal Microbiota Transplantation;
Hematologic Diseases;
Humans;
Treatment Outcome
- From:
Journal of Experimental Hematology
2019;27(1):306-310
- CountryChina
- Language:Chinese
-
Abstract:
Intestinal microbiome closely relates with human health and disease, which plays a critical role in the immune response, homeostasis, drug metabolism and tumorigenesis. Imbalances in the composition and function of these intestinal microbes associate with diseases. Fecal microbiota transplantation (FMT) is an established successful treatment modality for recurrent Clostridium difficile infection (CDI). The safety profile and potential therapeutic advantages of FMT for diseases associated with dysbiosis and immune dysfunction have led to many publications, mainly case series. The literature on the use of FMT for hematologic diseases is very limited, however, immune thrombocytopenic purpura（ITP）, CDI and aGVHD after HSCT were reported to be improved by FMT. The aim of this review is to briefly summarize the research current state, procedures and clinical application of FMT.
